| Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB K Gowrishankar, D Gunatilake, SJ Gallagher, J Tiffen, H Rizos, P Hersey PloS one 10 (4), e0123410, 2015 | 246 | 2015 |
| Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy A Al Emran, A Chatterjee, EJ Rodger, JC Tiffen, SJ Gallagher, MR Eccles, ... Trends in immunology 40 (4), 328-344, 2019 | 185 | 2019 |
| The ARF tumour suppressor SJ Gallagher, RF Kefford, H Rizos The international journal of biochemistry & cell biology 38 (10), 1637-1641, 2006 | 136 | 2006 |
| Beta-catenin inhibits melanocyte migration but induces melanoma metastasis SJ Gallagher, F Rambow, M Kumasaka, D Champeval, A Bellacosa, ... Oncogene 32 (17), 2230-2238, 2013 | 130 | 2013 |
| Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling A Heinemann, C Cullinane, R De Paoli-Iseppi, JS Wilmott, D Gunatilake, ... Oncotarget 6 (25), 21507, 2015 | 98 | 2015 |
| Control of NF‐kB activity in human melanoma by bromodomain and extra‐terminal protein inhibitor I‐BET 151 SJ Gallagher, B Mijatov, D Gunatilake, K Gowrishankar, J Tiffen, W James, ... Pigment cell & melanoma research 27 (6), 1126-1137, 2014 | 98 | 2014 |
| SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling T Strub, FG Ghiraldini, S Carcamo, M Li, A Wroblewska, R Singh, ... Nature communications 9 (1), 3440, 2018 | 86 | 2018 |
| Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes JC Tiffen, D Gunatilake, SJ Gallagher, K Gowrishankar, A Heinemann, ... Oncotarget 6 (29), 27023, 2015 | 80 | 2015 |
| Intralesional immunotherapy for melanoma P Hersey, S Gallagher Journal of surgical oncology 109 (4), 320-326, 2014 | 71 | 2014 |
| Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors F Lai, L Jin, S Gallagher, B Mijatov, XD Zhang, P Hersey Advances in pharmacology 65, 27-43, 2012 | 71 | 2012 |
| Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma A Chatterjee, EJ Rodger, A Ahn, PA Stockwell, M Parry, J Motwani, ... Iscience 4, 312-325, 2018 | 70 | 2018 |
| Automated cell tracking and analysis in phase-contrast videos (iTrack4U): development of Java software based on combined mean-shift processes FP Cordelières, V Petit, M Kumasaka, O Debeir, V Letort, SJ Gallagher, ... PloS one 8 (11), e81266, 2013 | 70 | 2013 |
| The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells SJ Gallagher, B Mijatov, D Gunatilake, JC Tiffen, K Gowrishankar, L Jin, ... Journal of Investigative Dermatology 134 (11), 2795-2805, 2014 | 68 | 2014 |
| The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance D Wroblewski, B Mijatov, N Mohana-Kumaran, F Lai, SJ Gallagher, ... Carcinogenesis 34 (2), 237-247, 2013 | 64 | 2013 |
| Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report HM McGuire, E Shklovskaya, J Edwards, PR Trevillian, GW McCaughan, ... Cancer Immunology, Immunotherapy 67, 563-573, 2018 | 62 | 2018 |
| EZH 2: An emerging role in melanoma biology and strategies for targeted therapy J Tiffen, SJ Gallagher, P Hersey Pigment cell & melanoma research 28 (1), 21-30, 2015 | 57 | 2015 |
| Epigenetic modulation in cancer immunotherapy SJ Gallagher, E Shklovskaya, P Hersey Current opinion in pharmacology 35, 48-56, 2017 | 54 | 2017 |
| EZH2 cooperates with DNA methylation to downregulate key tumor suppressors and IFN gene signatures in melanoma J Tiffen, SJ Gallagher, F Filipp, D Gunatilake, A Al Emran, C Cullinane, ... Journal of Investigative Dermatology 140 (12), 2442-2454. e5, 2020 | 52 | 2020 |
| p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors SJ Gallagher, JF Thompson, J Indsto, LL Scurr, M Lett, BF Gao, ... Neoplasia 10 (11), 1231-1239, 2008 | 52 | 2008 |
| HDAC inhibitors restore BRAF‐inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma SJ Gallagher, D Gunatilake, KA Beaumont, DM Sharp, JC Tiffen, ... International journal of cancer 142 (9), 1926-1937, 2018 | 48 | 2018 |
